MY168902A - Glycosylated polypeptide and pharmaceutical composition containing same - Google Patents
Glycosylated polypeptide and pharmaceutical composition containing sameInfo
- Publication number
- MY168902A MY168902A MYPI2014000925A MYPI2014000925A MY168902A MY 168902 A MY168902 A MY 168902A MY PI2014000925 A MYPI2014000925 A MY PI2014000925A MY PI2014000925 A MYPI2014000925 A MY PI2014000925A MY 168902 A MY168902 A MY 168902A
- Authority
- MY
- Malaysia
- Prior art keywords
- glycosylated polypeptide
- pharmaceutical composition
- composition containing
- containing same
- glycosylated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
- C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011218793 | 2011-10-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY168902A true MY168902A (en) | 2018-12-04 |
Family
ID=47995870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014000925A MY168902A (en) | 2011-10-01 | 2012-09-28 | Glycosylated polypeptide and pharmaceutical composition containing same |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10358470B2 (enExample) |
| EP (1) | EP2762489B1 (enExample) |
| JP (1) | JP6153470B2 (enExample) |
| KR (1) | KR101979045B1 (enExample) |
| CN (2) | CN104080803B (enExample) |
| AU (1) | AU2012317325B2 (enExample) |
| BR (1) | BR112014007766B1 (enExample) |
| CA (1) | CA2850469C (enExample) |
| DK (1) | DK2762489T3 (enExample) |
| IN (1) | IN2014CN02982A (enExample) |
| MY (1) | MY168902A (enExample) |
| PH (1) | PH12014500694B1 (enExample) |
| RU (1) | RU2636456C2 (enExample) |
| SG (2) | SG10201602076QA (enExample) |
| TW (1) | TWI633115B (enExample) |
| WO (1) | WO2013047846A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014CN02982A (enExample) | 2011-10-01 | 2015-07-03 | Glytech Inc | |
| AU2014245917B2 (en) * | 2013-03-29 | 2017-09-28 | Glytech, Inc. | Polypeptide having sialylated sugar chains attached thereto |
| CN114685645B (zh) * | 2020-12-30 | 2025-03-21 | 深圳翰宇药业股份有限公司 | 一种索玛鲁肽的合成方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0237019A3 (en) * | 1986-03-14 | 1988-03-09 | Toray Industries, Inc. | Interferon conjugate and production thereof using recombinant gene |
| AU736993B2 (en) | 1997-01-16 | 2001-08-09 | Novo Nordisk A/S | Practical in vitro sialylation of recombinant glycoproteins |
| DE19717864C2 (de) | 1997-04-23 | 2001-05-17 | Fraunhofer Ges Forschung | Humanes rekombinantes Interferon-beta, Verfahren zu seiner Herstellung und seine Verwendung |
| DE69936409T2 (de) * | 1998-04-28 | 2008-04-17 | Laboratoires Serono S.A., Coinsins | Verfahren zur schrittweise Bindung von Polyethylenglykol (PEG) an Polypeptide |
| DK1656952T3 (da) | 1998-10-16 | 2014-01-20 | Biogen Idec Inc | Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf |
| AU766190B2 (en) * | 1998-10-16 | 2003-10-09 | Biogen Idec Ma Inc. | Interferon-beta fusion proteins and uses |
| US6514729B1 (en) | 1999-05-12 | 2003-02-04 | Xencor, Inc. | Recombinant interferon-beta muteins |
| WO2001042474A2 (en) * | 1999-12-08 | 2001-06-14 | Amgen, Inc. | Interferon-like molecules and uses thereof |
| US7795002B2 (en) * | 2000-06-28 | 2010-09-14 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
| US20030191291A1 (en) | 2000-09-08 | 2003-10-09 | Kochendoerfer Gerd G. | Synthetic erythropoiesis stimulating proteins |
| EP1366075B1 (en) | 2001-02-27 | 2009-05-27 | Maxygen Aps | New interferon beta-like molecules |
| PL362870A1 (en) | 2001-03-15 | 2004-11-02 | Merck Patent Gmbh | Modified interferon beta with reduced immunogenicity |
| EP2292273A3 (en) * | 2001-10-10 | 2011-11-23 | BioGeneriX AG | Remodeling and glycoconjugation of peptides |
| US7226903B2 (en) * | 2001-10-10 | 2007-06-05 | Neose Technologies, Inc. | Interferon beta: remodeling and glycoconjugation of interferon beta |
| CA2469487A1 (en) | 2001-12-11 | 2003-07-03 | Aventis Pasteur | Mutated hiv tat |
| WO2003075944A2 (en) * | 2002-03-12 | 2003-09-18 | Maxygen Aps | Interferon beta-like molecules for treatment of stroke |
| US7943763B2 (en) | 2002-07-05 | 2011-05-17 | Otsuka Chemical Holdings Co., Ltd. | Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides |
| WO2004020468A2 (en) | 2002-08-28 | 2004-03-11 | Maxygen Aps | Interferon beta-like molecules for treatment of cancer |
| DK1575531T3 (da) * | 2002-09-27 | 2011-11-21 | Biogen Idec Inc | Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta |
| AU2003277088A1 (en) | 2002-10-01 | 2004-04-23 | Xencor, Inc | Interferon variants with improved properties |
| KR100876518B1 (ko) | 2002-12-26 | 2008-12-31 | 오츠카 가가쿠 가부시키가이샤 | 당사슬 아스파라긴 유도체 및 그의 제조방법 |
| WO2005019260A1 (ja) | 2003-08-25 | 2005-03-03 | Toray Industries, Inc. | インターフェロンβ複合体 |
| US20090214472A1 (en) | 2004-03-01 | 2009-08-27 | Enzon Pharmaceuticals Inc. | Interferon-beta polymer conjugates |
| MX2007001589A (es) | 2004-08-09 | 2007-08-02 | Alios Biopharma Inc | Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas. |
| RU2392963C2 (ru) * | 2004-08-09 | 2010-06-27 | Элиоз Байофарма, Инк. | Синтетические варианты гипергликозилированного протеазо-резистентного полипептида, пероральные композиции и способы применения таких вариантов |
| KR100781666B1 (ko) * | 2004-11-02 | 2007-12-03 | 신영기 | 인간 인터페론-베타 변이체 |
| US20080219952A1 (en) * | 2005-08-26 | 2008-09-11 | Ares Trading S.A. | Process For the Preparation of Glycosylated Interferon Beta |
| US20080038224A1 (en) * | 2006-03-28 | 2008-02-14 | Thierry Guyon | Modified interferon-beta (IFN-beta) polypeptides |
| US20080096819A1 (en) | 2006-05-02 | 2008-04-24 | Allozyne, Inc. | Amino acid substituted molecules |
| BRPI0813139A8 (pt) | 2007-06-19 | 2019-01-29 | Glytech Inc | peptídeo glp-1 com adição de cadeia oligossacarídea |
| KR101534881B1 (ko) | 2007-07-31 | 2015-07-07 | 가부시키가이샤 도우사 고가쿠 겐큐쇼 | 펩티드의 제조방법 |
| JP2009242372A (ja) | 2008-03-11 | 2009-10-22 | Yokohama City Univ | 均一な糖鎖構造を有するエリスロポエチン誘導体 |
| BRPI0914889A2 (pt) * | 2008-06-17 | 2015-11-24 | Otsuka Chemical Co Ltd | peptídeo glp-1 adicionado de cadeia oligossacarídica |
| CA2733362C (en) * | 2008-08-08 | 2016-10-18 | Universiteit Gent | Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof |
| AU2009283678B2 (en) * | 2008-08-19 | 2014-01-16 | Glytech, Inc. | Glycoprotein production method and screening method |
| WO2012051615A1 (en) | 2010-10-15 | 2012-04-19 | Transgenrx, Inc. | Novel vectors for production of glycosylated interferon |
| JP5925760B2 (ja) | 2011-03-10 | 2016-05-25 | 株式会社糖鎖工学研究所 | シアリル糖鎖を有する糖ペプチドの製造方法、当該製造方法に使用するシアリル糖鎖付加アミノ酸誘導体、及び当該糖ペプチド |
| ES2774284T3 (es) | 2011-06-29 | 2020-07-20 | Kyowa Kirin Co Ltd | Método para purificar antitrombina |
| IN2014CN02982A (enExample) | 2011-10-01 | 2015-07-03 | Glytech Inc |
-
2010
- 2010-08-18 IN IN2982CHN2014 patent/IN2014CN02982A/en unknown
-
2012
- 2012-09-28 CN CN201280058952.8A patent/CN104080803B/zh not_active Expired - Fee Related
- 2012-09-28 EP EP12836998.0A patent/EP2762489B1/en active Active
- 2012-09-28 CA CA2850469A patent/CA2850469C/en active Active
- 2012-09-28 RU RU2014116550A patent/RU2636456C2/ru active
- 2012-09-28 PH PH1/2014/500694A patent/PH12014500694B1/en unknown
- 2012-09-28 BR BR112014007766-5A patent/BR112014007766B1/pt not_active IP Right Cessation
- 2012-09-28 SG SG10201602076QA patent/SG10201602076QA/en unknown
- 2012-09-28 DK DK12836998.0T patent/DK2762489T3/en active
- 2012-09-28 MY MYPI2014000925A patent/MY168902A/en unknown
- 2012-09-28 SG SG11201401071YA patent/SG11201401071YA/en unknown
- 2012-09-28 KR KR1020147010631A patent/KR101979045B1/ko not_active Expired - Fee Related
- 2012-09-28 AU AU2012317325A patent/AU2012317325B2/en not_active Ceased
- 2012-09-28 JP JP2013536471A patent/JP6153470B2/ja not_active Expired - Fee Related
- 2012-09-28 US US14/347,222 patent/US10358470B2/en active Active
- 2012-09-28 WO PCT/JP2012/075262 patent/WO2013047846A1/ja not_active Ceased
- 2012-09-28 CN CN201811042210.1A patent/CN109134642A/zh active Pending
- 2012-10-01 TW TW101136177A patent/TWI633115B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PH12014500694B1 (en) | 2020-01-31 |
| IN2014CN02982A (enExample) | 2015-07-03 |
| TW201321404A (zh) | 2013-06-01 |
| TWI633115B (zh) | 2018-08-21 |
| EP2762489B1 (en) | 2018-03-28 |
| SG10201602076QA (en) | 2016-04-28 |
| CA2850469C (en) | 2020-07-07 |
| US10358470B2 (en) | 2019-07-23 |
| BR112014007766A2 (pt) | 2017-04-04 |
| KR20140095051A (ko) | 2014-07-31 |
| SG11201401071YA (en) | 2014-08-28 |
| RU2636456C2 (ru) | 2017-11-23 |
| CN104080803A (zh) | 2014-10-01 |
| WO2013047846A1 (ja) | 2013-04-04 |
| EP2762489A4 (en) | 2015-05-06 |
| JP6153470B2 (ja) | 2017-06-28 |
| AU2012317325A1 (en) | 2014-04-17 |
| JPWO2013047846A1 (ja) | 2015-03-30 |
| EP2762489A9 (en) | 2015-02-11 |
| AU2012317325B2 (en) | 2016-10-06 |
| CN104080803B (zh) | 2020-08-04 |
| EP2762489A1 (en) | 2014-08-06 |
| BR112014007766B1 (pt) | 2022-05-10 |
| RU2014116550A (ru) | 2015-10-27 |
| DK2762489T3 (en) | 2018-07-02 |
| PH12014500694A1 (en) | 2014-05-12 |
| CA2850469A1 (en) | 2013-04-04 |
| US20140369964A1 (en) | 2014-12-18 |
| KR101979045B1 (ko) | 2019-05-15 |
| CN109134642A (zh) | 2019-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202201361B (en) | Methods and compositions comprising purified recombinant polypeptides | |
| GB2496337A (en) | Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases | |
| MX358224B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado. | |
| MX2013001982A (es) | Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro | |
| MX2015012034A (es) | El péptido mots3 derivado de mitocondrias regula el metabolismo y supervivencia celular. | |
| WO2013060867A3 (en) | Production of heterodimeric proteins | |
| NZ705370A (en) | Fcγriib-specific fc region variant | |
| PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
| MY180672A (en) | Ace2 polypeptide | |
| HK1206636A1 (zh) | 用於制备肿瘤相关蛋白和多肽的修饰的多核苷酸 | |
| MD20150091A2 (ro) | Compuşi antivirali | |
| EA201391489A1 (ru) | Композиции со сниженной вязкостью | |
| MX357965B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar. | |
| MX341324B (es) | Polipeptidos. | |
| EA201391175A1 (ru) | Гетеродимерные иммуноглобулины | |
| MX351414B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
| MX363788B (es) | Métodos para la producción de polipéptidos procesados proteolíticamente. | |
| NZ717035A (en) | Cortistatin analogues for the treatment of inflammatory and/or immune diseases | |
| MX2013000793A (es) | Composicion que contiene galacto-oligosacarido y un metodo para producirla. | |
| EA201391488A1 (ru) | Композиции со сниженной вязкостью | |
| UA116889C2 (uk) | Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc) | |
| EA201400850A1 (ru) | Альфа-амилаза | |
| MX2016007407A (es) | Peptidos resistentes a proteasa. | |
| EA201190274A1 (ru) | Конструкции casb7439 | |
| ZA201209566B (en) | Novel glucagon like peptide analogs,composition,and method of use |